Jeremy Force

Positions:

Assistant Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

D.O. 2011

University of New England

Internal Medicine Residency

Indiana University, School of Medicine

Hematology/Oncology Fellowship, Medicine

Duke University School of Medicine

Grants:

A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer

Administered By
Duke Cancer Institute
Awarded By
Fox Chase Cancer Center
Role
Principal Investigator
Start Date
End Date

Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer protocol # TBCRC 039

Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Role
Principal Investigator
Start Date
End Date

A Phase II randomized study to evaluate the immunologic and antitumor activity of concurrent VRP-HER2 vaccination and Pembrolizumab for patients with advanced HER2-overexpressing breast cancer

Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Role
Principal Investigator
Start Date
End Date

TBCRC 047

Administered By
Duke Cancer Institute
Awarded By
Johns Hopkins University
Role
Principal Investigator
Start Date
End Date

Publications:

Abstract P1-06-04: Small-molecule screening nominates diverse combination therapies that sensitize BRCA mutant and wild-type triple negative breast cancer to PARP inhibition

Authors
Sammons, S; Yip, C; Anderson, G; Force, J; Marcom, K; Westbrook, K; Anders, CK; Blackwell, K; Wood, K
MLA Citation
Sammons, S., et al. “Abstract P1-06-04: Small-molecule screening nominates diverse combination therapies that sensitize BRCA mutant and wild-type triple negative breast cancer to PARP inhibition.” Poster Session Abstracts, American Association for Cancer Research, 2019. Crossref, doi:10.1158/1538-7445.sabcs18-p1-06-04.
URI
https://scholars.duke.edu/individual/pub1404187
Source
crossref
Published In
Poster Session Abstracts
Published Date
DOI
10.1158/1538-7445.sabcs18-p1-06-04

Surgery for Men with Breast Cancer: Do the Same Data Still Apply?

BACKGROUND: Men represent a small proportion of breast cancer diagnoses, and they are often excluded from clinical trials. Current treatments are largely extrapolated from evidence in women. We compare practice patterns between men and women with breast cancer following the publication of several landmark clinical trials in surgery. PATIENTS AND METHODS: Patients with invasive breast cancer (2004-2015) from the National Cancer Data Base were identified; subcohorts were created based on eligibility for NSABP-B06, CALGB 9343, and ACOSOG Z0011. Practice patterns were stratified by gender and compared. Cox proportional hazards regression analyses were utilized to estimate the association between OS and gender. RESULTS: Of the 1,664,746 patients identified, 99% were women and 1% were men. Among NSABP-B06 eligible men, mastectomy rates did not change (consistently ~ 80%), and their adjusted OS was minimally worse compared with women (HR 1.19, 95% CI 1.11-1.28). Following publication of CALGB 9343, omission of radiation after lumpectomy was less likely in men and lagged behind that of women, despite similar OS (male HR 0.92, 95% CI 0.59-1.44). Application of ACOSOG Z0011 findings resulted in deescalation of axillary surgery for men and women with comparable OS (male HR 0.69, 95% CI 0.33-1.45). CONCLUSIONS: Uptake of clinical trial results for men with breast cancer often mirrors that for women, despite exclusion from these studies. Furthermore, when study findings were applied to eligible patients, men and women demonstrated similar survival. Observational studies can help inform the potential application of study findings to this unique population and improve patient enrollment in clinical trials.
Authors
MLA Citation
Plichta, Jennifer K., et al. “Surgery for Men with Breast Cancer: Do the Same Data Still Apply?Ann Surg Oncol, July 2020. Pubmed, doi:10.1245/s10434-020-08901-z.
URI
https://scholars.duke.edu/individual/pub1452159
PMID
32705510
Source
pubmed
Published In
Annals of Surgical Oncology
Published Date
DOI
10.1245/s10434-020-08901-z

Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer

Authors
Force, J; Qin, X; Zhang, D; Marcom, PK; Marks, J; Taylor, ML; Anders, C; Owzar, K; Xie, J
MLA Citation
Force, Jeremy, et al. “Abstract P1-06-02: Characterization of gene- and sample-level APOBEC mutagenesis enrichment with respect to intrinsic subtypes, tumor mutational burden, and immune composition in breast cancer.” Poster Session Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7445.sabcs19-p1-06-02.
URI
https://scholars.duke.edu/individual/pub1442732
Source
crossref
Published In
Poster Session Abstracts
Published Date
DOI
10.1158/1538-7445.sabcs19-p1-06-02

Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer

MLA Citation
Sammons, Sarah, et al. “Abstract P3-08-10: Characterization of oncotype DX recurrence score and chemotherapy utilization patterns in young women (≤40) with early stage ER+/HER-, lymph node negative breast cancer.” Poster Session Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7445.sabcs19-p3-08-10.
URI
https://scholars.duke.edu/individual/pub1442733
Source
crossref
Published In
Poster Session Abstracts
Published Date
DOI
10.1158/1538-7445.sabcs19-p3-08-10

Abstract P3-06-09: Incidence of ROS1 genomic alterations in breast cancer

Authors
Force, J; Sokol, ES; Taylor, ML; Huang, D; Marcom, PK; Davare, M; Marks, J
MLA Citation
Force, Jeremy, et al. “Abstract P3-06-09: Incidence of ROS1 genomic alterations in breast cancer.” Poster Session Abstracts, American Association for Cancer Research, 2020. Crossref, doi:10.1158/1538-7445.sabcs19-p3-06-09.
URI
https://scholars.duke.edu/individual/pub1444178
Source
crossref
Published In
Poster Session Abstracts
Published Date
DOI
10.1158/1538-7445.sabcs19-p3-06-09

Research Areas:

APOBEC
BRCA genes
Breast--Cancer--Immunotherapy
Cancer/testis Antigens
Homologous Recombination
Inflammatory Breast Cancer
Nanostring
Tumor Immune Microenvironment
Tumor Infiltrating Lymphocytes
X Chromosome Inactivation
X chromosome--Abnormalities